Literature DB >> 25405694

Prevention of peri-induction hypertension in preeclamptic patients: a focused review.

Melissa Pant1, Robert Fong, Barbara Scavone.   

Abstract

Many medications have been used to prevent the hypertensive response to the induction of general anesthesia and laryngoscopy in preeclamptic patients, with varying results. In this focused review, we summarize the available data and pharmacologic profiles of these drugs. Several different drug classes may be used safely; however, magnesium bolus, lidocaine, calcium channel antagonists other than nicardipine, and hydralazine are not recommended. Further research is warranted into the hemodynamic impact of varying the induction drug dose or combining different classes of drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405694     DOI: 10.1213/ANE.0000000000000424

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

Review 1.  [The new S1 guidelines "Obstetric analgesia and anesthesia"-Presentation and comments].

Authors:  Dorothee H Bremerich; Susanne Greve
Journal:  Anaesthesist       Date:  2021-01-19       Impact factor: 1.041

2.  Comparison of Haemodynamic Response to Inhalational Bolus with Desflurane in Normotensive and Hypertensive Patients Undergoing Laparoscopic Cholecystectomy.

Authors:  Kamlesh Kumari; Tanvir Samra; Vikas Saini; Sameer Sethi; Neerja Banerjee; Sujata Sharma
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-05-02

3.  Anesthetic Management of a Parturient with Hemolysis, Elevated Liver Enzyme Levels, and Low Platelet Syndrome Complicated by Renal Insufficiency and Coagulopathy.

Authors:  Jinguo Wang; Na Wang; Wei Han; Zhanyang Han
Journal:  Anesth Essays Res       Date:  2017 Oct-Dec

4.  [Special pathologies of pregnant patients in intensive care medicine].

Authors:  Sophie Neuhaus; Christopher Neuhaus; Markus A Weigand; Dorothee Bremerich
Journal:  Anaesthesist       Date:  2021-04-13       Impact factor: 1.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.